Dronedarone in patients with atrial fibrillation

作者：de Groot N M S^*; Kirchhof C J; van Gelder I C; Meeder J G; Balk A H M M; Wilde A A; Simoons M L

来源：Netherlands Heart Journal, 2010, 18(7-8): 370-373.

• Donedarone
• Amiodarone
• Anti-Arrhythmia Agents
• Atrial Fibrillation

Dronedarone is a recently developed new class III antiarrhythmic drug which possesses electrophysiological properties of all four Vaughan-Williams classes. An important difference with amiodarone is that it does not contain an iodine component and therefore lacks the iodine-related adverse effects. Based on currently available data, dronedarone can not be recommended as first-line therapy for either rhythm or rate control. We recommend to initiate rhythm or rate control with drugs as indicated in the 2006 guidelines of the ESC and other organisations. As amiodarone, dronedarone can be given to patients for whom standard drug therapy is not effective, or limited by (severe) side effects, although it is less effective than amiodarone. Nevertheless, it may be considered to give dronedarone initially to patients who would otherwise have received amiodarone, since the latter has more severe side effects than the former drug. The daily dosage of dronedarone is oral administration, 400 mg twice daily. Dronedarone is contraindicated in patients with impaired left ventricular NYHA class III/IV) and haemodynamic instability. (Neth Heart J 2010;18:370-3.)

• 出版日期2010-8